Overview

Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma

Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, single-arm, multicenter clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade combined with induction chemotherapy and radiotherapy alone in high-risk locoregionally advanced nasopharyngeal carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Bristol-Myers Squibb
Varian Medical Systems, Inc.
Treatments:
Antibodies
Antibodies, Blocking
Cisplatin
Gemcitabine
Immunoglobulins